[
  {
    "ts": "2026-01-08T02:18:03+00:00",
    "headline": "Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks",
    "summary": "We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]",
    "url": "https://finance.yahoo.com/news/revolution-medicines-rvmd-hits-time-021803051.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d41f9ce8-a0b1-359c-8449-1416338d888a",
      "content": {
        "id": "d41f9ce8-a0b1-359c-8449-1416338d888a",
        "contentType": "STORY",
        "title": "Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks",
        "description": "",
        "summary": "We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]",
        "pubDate": "2026-01-08T02:18:03Z",
        "displayTime": "2026-01-08T02:18:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a",
          "originalWidth": 768,
          "originalHeight": 474,
          "caption": "I'll Play, Says Jim Cramer About Bristol-Myers (BMY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mwG_K7ERKsXp5c8CgY3M_w--~B/aD00NzQ7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a.cf.webp",
              "width": 768,
              "height": 474,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qq.4GqsrpbstuiBHkHyOXg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-rvmd-hits-time-021803051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-rvmd-hits-time-021803051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T11:10:38+00:00",
    "headline": "Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?",
    "summary": "AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...",
    "url": "https://finance.yahoo.com/news/health-canada-eight-week-maviret-111038793.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b91d8c6f-88e0-3963-b6ab-2a98a9ac07f5",
      "content": {
        "id": "b91d8c6f-88e0-3963-b6ab-2a98a9ac07f5",
        "contentType": "STORY",
        "title": "Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?",
        "description": "",
        "summary": "AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...",
        "pubDate": "2026-01-08T11:10:38Z",
        "displayTime": "2026-01-08T11:10:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/health-canada-eight-week-maviret-111038793.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/health-canada-eight-week-maviret-111038793.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T04:38:05+00:00",
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
    "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
    "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043805181.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "badb6cb6-54de-3c4a-ac1f-b891a955f5b7",
      "content": {
        "id": "badb6cb6-54de-3c4a-ac1f-b891a955f5b7",
        "contentType": "STORY",
        "title": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
        "description": "",
        "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
        "pubDate": "2026-01-08T04:38:05Z",
        "displayTime": "2026-01-08T04:38:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2a3b1bb7c675085376ea87403023d161",
          "originalWidth": 2400,
          "originalHeight": 1602,
          "caption": "ONTF Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cK3PMXU9wiWEHtPm2zwLZg--~B/aD0xNjAyO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/2a3b1bb7c675085376ea87403023d161.cf.webp",
              "width": 2400,
              "height": 1602,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R5rqQF4VFmud1n5ZuFB22g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2a3b1bb7c675085376ea87403023d161.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043805181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-unpopular-stock-deserves-second-043805181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ONTF"
            },
            {
              "symbol": "ZION"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]